Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 6/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789317 | 0.89 | SLC6A3 (0.50) | QPCTALDH1A1LMNASLC6A3 | |
| SCHEMBL4553224 | 0.81 | ATM (0.43) | QPCTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL12732596 | 0.76 | QPCT (0.87) | QPCTHDAC6 | |
| SCHEMBL31663152 | 0.76 | GAA (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15775916 | 0.76 | MEN1 (0.39) | QPCTALDH1A1MEN1KMT2A | |
| SCHEMBL22560034 | 0.76 | MEN1 (0.42) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1 | |
| SCHEMBL2234874 | 0.76 | GAA (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1444543 | 0.75 | QPCT (0.72) | QPCT | |
| SCHEMBL6629235 | 0.75 | MAPT (0.55) | QPCTALDH1A1CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL523273 | 0.73 | ESR1 (0.62) | ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3468954-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | QPCT 1573/4885HDAC6 1723/4885ALDH1A1 1290/4885 |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | QPCT 202/4885HDAC6 377/4885ALDH1A1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.